Free PSA/Total PSA Ratio Increases the Detection Rate of Prostate Cancer in Twelve-Core Biopsy | Semantic Scholar
Measurement of total and free prostate specific antigen (PSA) in human serum samples using an ultra-microanalytical system - ScienceDirect
PSA Velocity and Prostate Cancer | NEJM
Cell-Free Circulating Plasma hTERT mRNA Is a Useful Marker for Prostate Cancer Diagnosis and Is Associated with Poor Prognosis Tumor Characteristics | PLOS ONE
Prostate Cancer Screening with PSA and MRI Followed by Targeted Biopsy Only | NEJM
The Predictive Ability of Prostate-Specific Antigen (PSA) Density and Free/Total PSA Ratio in Diagnosing Clinically Significant Prostate Cancer (PCa) in Patients with Histologically Confirmed PCa with a PSA Level of 2.5-10 Ng/ML. -
Isolated prostate cancer soft tissue recurrence 10 years after radical prostatectomy | BMJ Case Reports
Undetectable PSA Levels Tied to Improvements in rPFS, OS in Metastatic Hormone-Sensitive Prostate Cancer - Oncology Nurse Advisor
CD8+ T Cells Impact Rising PSA in Biochemically Relapsed Cancer Patients Using Immunotherapy Targeting Tumor-Associated Antigens: Molecular Therapy
Optimizing anti-androgen treatment use among men with pathologic lymph-node positive prostate cancer treated with radical prostatectomy: the importance of postoperative PSA kinetics | Prostate Cancer and Prostatic Diseases
Forest plot of ≥50% decline in PSA AA Antiandrogen, 95% CI 95%... | Download Scientific Diagram
Diagnostic Performance and Clinical Impact of 68Ga-PSMA-11 PET/CT Imaging in Early Relapsed Prostate Cancer After Radical Therapy: A Prospective Multicenter Study (IAEA-PSMA Study) | Journal of Nuclear Medicine
Table 1 from Very low PSA concentrations and deletions of the KLK3 gene. | Semantic Scholar
Ethnicity Is an Independent Determinant of Age-Specific PSA Level: Findings from a Multiethnic Asian Setting | PLOS ONE
ICUrology :: Investigative and Clinical Urology
Solved Please check my work for me and solve the rest of it! | Chegg.com
ESMO 2022: Association between prostate-specific antigen decline and clinical outcomes in patients with metastatic castration-resistant prostate cancer in the VISION trial